Multiple signalling pathways underlie the protective effect of levosimendan in cardiac myocytes

European Journal of Pharmacology

Volumn 667, Issue 1-3, 2011, Pages 298-305

  Markou, Thomais ^a   Makridou, Zoe ^a   Galatou, Eleftheria ^a   Lazou, Antigone ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Akt; Cardiac myocyte; Ischaemia; Levosimendan; MAPK; Signalling pathway

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CYCLIC AMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; LEVOSIMENDAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B;

ANIMAL CELL; ARTICLE; CELL DAMAGE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART MUSCLE CELL; HEART PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOTONIC AGENTS; CYTOPROTECTION; HYDRAZONES; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCYTES, CARDIAC; OXYGEN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDAZINES; RATS; RATS, WISTAR; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 80052029553     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.05.078     Document Type: Article

References (45)

1. Y. Ajiro, N. Hagiwara, Y. Katsube, N. Sperelakis, and H. Kasanuki Levosimendan increases L-type Ca(2+) current via phosphodiesterase-3 inhibition in human cardiac myocytes Eur. J. Pharmacol. 435 2002 27 33 (Pubitemid 34094972)
2. R. Bassi, R. Heads, M.S. Marber, and J.E. Clark Targeting p38-MAPK in the ischaemic heart: kill or cure? Curr. Opin. Pharmacol. 8 2008 141 146
3. P. Bokník, J. Neumann, G. Kaspareit, W. Schmitz, H. Scholz, and U. Vahlensieck Mechanisms of the contractile effects of levosimendan in the mammalian heart J. Pharmacol. Exp. Ther. 280 1997 277 283 (Pubitemid 27171413)
4. B. Das, and C. Sarkar Pharmacological preconditioning by levosimendan is mediated by inducible nitric oxide synthase and mitochondrial KATP channel activation in the in vivo anesthetized rabbit heart model Vascul. Pharmacol. 47 2007 248 256 (Pubitemid 47470049)
5. E.F. Du Toit, A. Genis, L.H. Opie, P. Pollesello, and A. Lochner A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart Br. J. Pharmacol. 154 2008 41 50 (Pubitemid 351620393)
6. I. Edes, E. Kiss, Y. Kitada, F.M. Powers, J.G. Papp, E.G. Kranias, and R.J. Solaro Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart Circ. Res. 77 1995 107 113
7. S.J. Fuller, K. Sivarajah, and P.H. Sugden ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium J. Mol. Cell. Cardiol. 44 2008 831 854
8. G.J. Gross, and J.N. Peart KATP channels and myocardial preconditioning: an update Am. J. Physiol. Heart Circ. Physiol. 285 2003 H921 H930
9. E. Grossini, C. Molinari, P.P. Caimmi, F. Uberti, and G. Vacca Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel Br. J. Pharmacol. 156 2009 250 261
10. H. Haikala, E. Nissinen, E. Etemadzadeh, J. Levijoki, and I.B. Lindén Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation J. Cardiovasc. Pharmacol. 25 1995 794 801
11. D.J. Hausenloy Signalling pathways in ischaemic postconditioning Thromb. Haemost. 101 2009 626 634
12. D.J. Hausenloy, and D.M. Yellon Survival kinases in ischemic preconditioning and postconditioning Cardiovasc. Res. 70 2006 240 253
13. D.J. Hausenloy, A. Tsang, M.M. Mocanu, and D.M. Yellon Ischemic preconditioning protects by activating prosurvival kinases at reperfusion Am. J. Physiol. Heart Circ. Physiol. 288 2005 H971 H976
14. A. Hönisch, N. Theuring, B. Ebner, C. Wagner, R.H. Strasser, and C. Weinbrenner Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition Basic. Res. Cardiol. 105 2009 155 167
15. E.K. Iliodromitis, C. Gaitanaki, A. Lazou, E. Bofilis, G.K. Karavolias, I. Beis, and D.T. Kremastinos Dissociation of stress-activated protein kinase (p38-MAPK and JNKs) phosphorylation from the protective effect of preconditioning in vivo J. Mol. Cell. Cardiol. 34 2002 1019 1028 (Pubitemid 35316149)
16. E.K. Iliodromitis, C. Gaitanaki, A. Lazou, I.K. Aggeli, V. Gizas, E. Bofilis, A. Zoga, I. Beis, and D.T. Kremastinos Differential activation of mitogen-activated protein kinases in ischemic and nitroglycerin-induced preconditioning Basic. Res. Cardiol. 101 2006 327 335 (Pubitemid 43923389)
17. P. Kaheinen, P. Pollesello, J. Levijoki, and H. Haikala Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels J. Cardiovasc. Pharmacol. 37 2001 367 374 (Pubitemid 32240418)
18. G. Kang, C.A. Leech, O.G. Chepurny, W.A. Coetzee, and G.G. Holz Role of the cAMP sensor Epac as a determinant of KATP channel ATP sensitivity in human pancreatic beta-cells and rat INS-1 cells J. Physiol. 586 2008 1307 1319 (Pubitemid 351321270)
19. E. Kefaloyianni, C. Gaitanaki, and I. Beis ERK1/2 and p38-MAPK signalling pathways, through MSK1, are involved in NF-kappaB transactivation during oxidative stress in skeletal myoblasts Cell. Signal. 18 2006 2238 2251 (Pubitemid 44740489)
20. J.R. Kersten, M.W. Montgomery, P.S. Pagel, and D.C. Warltier Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels Anesth. Analg. 90 2000 5 11 (Pubitemid 30022959)
21. D.M. Kopustinskiene, P. Pollesello, and N.E. Saris Levosimendan is a mitochondrial K(ATP) channel opener Eur. J. Pharmacol. 428 2001 311 314 (Pubitemid 33016646)
22. M. Krenz, O. Oldenburg, H. Wimpee, M.V. Cohen, K.D. Garlid, S.D. Critz, J.M. Downey, and J.N. Benoit Opening of ATP-sensitive potassium channels causes generation of free radicals in vascular smooth muscle cells Basic. Res. Cardiol. 97 2002 365 373
23. A. Lazou, E.K. Iliodromitis, D. Cieslak, K. Voskarides, S. Mousikos, E. Bofilis, and D.T. Kremastinos Ischemic but not mechanical preconditioning attenuates ischemia/reperfusion induced myocardial apoptosis in anaesthetized rabbits: the role of Bcl-2 family proteins and ERK1/2 Apoptosis 11 2006 2195 2204 (Pubitemid 44885395)
24. I. Leprán, and J.G. Papp Effect of long-term oral pretreatment with levosimendan on cardiac arrhythmias during coronary artery occlusion in conscious rats Eur. J. Pharmacol. 464 2003 171 176 (Pubitemid 36293737)
25. I. Leprán, P. Pollesello, S. Vajda, A. Varró, and J.G. Papp Preconditioning effects of levosimendan in a rabbit cardiac ischemia-reperfusion model J. Cardiovasc. Pharmacol. 48 2006 148 152 (Pubitemid 44691216)
26. T.H. Leu, and M.C. Maa Functional implication of the interaction between EGF receptor and c-Src Front. Biosci. 8 2003 28 38
27. T. Markou, D. Cieslak, C. Gaitanaki, and A. Lazou Differential roles of MAPKs and MSK1 signalling pathways in the regulation of c-Jun during phenylephrine-induced cardiac myocyte hypertrophy Mol. Cell. Biochem. 322 2009 103 112
28. M. Maytin, and W.S. Colucci Cardioprotection: a new paradigm in the management of acute heart failure syndromes Am. J. Cardiol. 96 2005 26G 31G (Pubitemid 41338071)
29. A. Nakano, M.V. Cohen, S. Critz, and J.M. Downey SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts Basic. Res. Cardiol. 95 2000 466 471 (Pubitemid 32013986)
30. O. Oldenburg, M.V. Cohen, D.M. Yellon, and J.M. Downey Mitochondrial K(ATP) channels: role in cardioprotection Cardiovasc. Res. 55 2002 429 437 (Pubitemid 34874938)
31. O. Oldenburg, Q. Qin, A.R. Sharma, M.V. Cohen, J.M. Downey, and J.N. Benoit Acetylcholine leads to free radical production dependent on K(ATP) channels, G(i) proteins, phosphatidylinositol 3-kinase and tyrosine kinase Cardiovasc. Res. 55 2002 544 552 (Pubitemid 34874949)
32. J. Pataricza, J. Hõhn, A. Petri, A. Balogh, and J.G. Papp Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein J. Pharm. Pharmacol. 52 2000 213 217 (Pubitemid 30125304)
33. A. Punn, J.W. Mockridge, S. Farooqui, M.S. Marber, and R.J. Heads Sustained activation of p42/p44 mitogen-activated protein kinase during recovery from simulated ischaemia mediates adaptive cytoprotection in cardiomyocytes Biochem. J. 350 2000 891 899
34. S. Purdom, and Q.M. Chen Epidermal growth factor receptor-dependent and -independent pathways in hydrogen peroxide-induced mitogen-activated protein kinase activation in cardiomyocytes and heart fibroblasts J. Pharmacol. Exp. Ther. 312 2005 1179 1186 (Pubitemid 40293779)
35. A. Raasmaja, A. Talo, E. Nissinen, I.B. Linden, and P. Pohto Biochemical mechanisms of the novel cardiotonic agent OR-1259 J. Mol. Cell. Cardiol. 23 Suppl V 1991 S129
36. T. Ravingerová, M. Barancík, and M. Strnisková Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology Mol. Cell. Biochem. 247 2003 127 138 (Pubitemid 36798517)
37. A.F. Rump, D. Acar, R. Rösen, and W. Klaus Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts Pharmacol. Toxicol. 74 1994 244 248 (Pubitemid 24154962)
38. K. Sato, A. Sato, M. Aoto, and Y. Fukami c-Src phosphorylates epidermal growth factor receptor on tyrosine 845 Biochem. Biophys. Res. Commun. 215 1995 1078 1087
39. P.H. Sugden, and A. Clerk Oxidative stress and growth-regulating intracellular signaling pathways in cardiac myocytes Antioxid. Redox Signal. 8 2006 2111 2124 (Pubitemid 46489635)
40. S. Szilágyi, P. Pollesello, J. Levijoki, P. Kaheinen, H. Haikala, I. Edes, and Z. Papp The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig Eur. J. Pharmacol. 486 2004 67 74 (Pubitemid 38130162)
41. K. Todaka, J. Wang, G.H. Yi, R. Stennett, M. Knecht, M. Packer, and D. Burkhoff Effects of levosimendan on myocardial contractility and oxygen consumption J. Pharmacol. Exp. Ther. 279 1996 120 127 (Pubitemid 27166902)
42. C. Weinbrenner, G.S. Liu, M.V. Cohen, and J.M. Downey Phosphorylation of tyrosine 182 of p38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart J. Mol. Cell. Cardiol. 29 1997 2383 2391 (Pubitemid 27404431)
43. Z. Xu, X. Ji, and P.G. Boysen Exogenous nitric oxide generates ROS and induces cardioprotection: involvement of PKG, mitochondrial KATP channels, and ERK Am. J. Physiol. Heart Circ. Physiol. 286 2004 H1433 H1440
44. H. Yokoshiki, Y. Katsube, M. Sunagawa, and N. Sperelakis Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes Eur. J. Pharmacol. 333 1997 249 259 (Pubitemid 27387398)
45. P. Zoltán, C. Kálmán, P. Pollesello, H. Haikala, and I. Édes Pharmacological mechanisms contributing to the clinical efficacy of levosimendan Cardiovasc. Drug Rev. 23 2005 71 98